Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | PKLR | P30613 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6404329 | 1.00 | CYP1A2 (0.55) | CYP1A2TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL6695015 | 1.00 | CYP1A2 (0.55) | CYP1A2TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL5582438 | 0.87 | MEN1 (0.54) | CYP1A2TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL5582440 | 0.87 | MEN1 (0.54) | CYP1A2TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL5582439 | 0.87 | MEN1 (0.54) | CYP1A2TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL9068346 | 0.85 | MEN1 (0.53) | CYP1A2TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL28062163 | 0.85 | KMT2A (0.53) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL2003175 | 0.85 | MEN1 (0.53) | CYP1A2TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL6615901 | 0.84 | RAB9A (0.53) | MEN1KMT2AALDH1A1RAB9AGAA | |
| SCHEMBL6615905 | 0.84 | RAB9A (0.53) | MEN1KMT2AALDH1A1RAB9AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6908921-B2 | Quinoxalinone derivatives as bradykinin B1 antagonists | MERCK & CO., INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20050020591-A1 | 2-Quinoxalinone derivatives as bradykinin antagonists and novel compounds | SU DAI-SHI (US) | 2005-01-27 | — | — | US | disclosed |
| US-20040235849-A1 | Tetrahydroquinoxalines acting as bradykinin antagonists | BAYER HEALTHCARE AG (DE) | 2004-11-25 | — | — | US | disclosed |
| US-20040132733-A1 | Novel quinoxalinone derivatives as bradykinin B1 antagonists | MERCK & CO., INC. | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235849-A1 | Tetrahydroquinoxalines acting as bradykinin antagonists | BDKRB2, BDKRB1, LTB4R2 | CYP1A2 1922/4885TSHR 3674/4885MEN1 1108/4885 |
| US-20050020591-A1 | 2-Quinoxalinone derivatives as bradykinin antagonists and novel compounds | BDKRB1, BDKRB2, LTB4R2 | CYP1A2 1298/4885TSHR 3915/4885MEN1 2130/4885 |
| US-20040132733-A1 | Novel quinoxalinone derivatives as bradykinin B1 antagonists | BDKRB1, BDKRB2, LTB4R2 | CYP1A2 1347/4885TSHR 3950/4885MEN1 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.